Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARALAST NP
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
ARALAST NP is a plasma-derived human alpha-1 proteinase inhibitor (A1PI) indicated for chronic augmentation therapy in adults with clinically evident emphysema due to severe congenital alpha-1 proteinase inhibitor deficiency (Alpha-1 antitrypsin deficiency). Developed by Baxalta (later acquired by Shire and subsequently Takeda), it is supplied as a sterile, lyophilized powder for reconstitution and administered via once-weekly intravenous infusion. The therapy works by increasing antigenic and functional serum levels and lung epithelial lining fluid levels of A1PI, which restores the capacity to inhibit neutrophil elastase. This inhibition protects the lung parenchyma from proteolytic damage and slows the progression of emphysema in patients with severe deficiency.
- Brand names
- ARALAST NP
- Other names
- alpha 1-proteinase inhibitor (human)alpha-1 antitrypsinalpha1 antitrypsinalpha 1 antitrypsinAATA1PIA-1PIA 1PI
02
Targets
ELANE (Human Neutrophil Elastase)
Beyond the preview
Go deeper on ARALAST NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARALAST NP.